Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Objectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Tian Xu, Yilin Ruan, Na Liu, Yi Wang, Xiujuan Zang, Yuhua Ma, Hualin Qi, Xiuhua Mi, Geping Yu, Chunyan Zhang, Xiaomin Huang, Jingyuan Xie, Nan Chen, Hong Ren
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Renal Failure
Subjects:
Roxadustat
blood lipids
peritoneal dialysis
anemia
iron metabolism
Online Access:https://www.tandfonline.com/doi/10.1080/0886022X.2025.2460726
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.Methods In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.Results At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.Conclusions Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.
ISSN:0886-022X
1525-6049

Similar Items